{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:39:59Z","timestamp":1793932799886,"version":"4.8.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"\n Importance<\/jats:title>\n \n Friedreich ataxia (FA), a fatal, autosomal recessive disorder caused by pathogenic variants in the frataxin (\n FXN<\/jats:italic>\n ) gene, is characterized by progressive neurologic and cardiac disease, with cardiac disease being the major cause of death. Preclinical studies have demonstrated that systemic administration of AAVrh.10hFXN, an rh.10 serotype cardiotropic adenoassociated virus (AAV) vector expressing the normal human\n FXN<\/jats:italic>\n coding sequence, reverses the cardiomyopathy in FXN-deficient mice.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the safety and preliminary efficacy of administration of AAVrh.10hFXN to adults with FA cardiomyopathy.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This nonrandomized clinical trial evaluates the pooled data of 2 independent, open-label, dose-escalation trials that used the same gene therapy vector and similar clinical protocols among patients with FA cardiomyopathy at academic medical centers. Data were collected from February 22, 2022, to October 4, 2025, for trial 1 and from February 14, 2023, to September 10, 2025, for trial 2 and analyzed together from November 5, 2025, to March 12, 2026.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n \n AAVrh.10hFXN, administered intravenously in 3 dose cohorts (1.8\u2009\u00d7\u200910\n 11<\/jats:sup>\n , 5.6\u2009\u00d7\u200910\n 11<\/jats:sup>\n , and 1.2\u2009\u00d7\u200910\n 12<\/jats:sup>\n vector genomes per kilogram of body weight).\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n In addition to safety as the primary outcome, multiple parameters of exploratory end points were assessed, including cardiac biopsy levels of FXN protein, cardiac magnetic resonance imaging\u2013derived left ventricular mass index (LVMI), and serum high-sensitivity (hs) troponin I.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Seventeen patients with FA cardiomyopathy (mean [SD] age, 25 [6] years; 11 [65%] female) were followed up for a mean (SD) of 20 (8) months. There were 4 serious adverse events, 3 possibly related to prednisone immunosuppression and 1 possibly vector-related myocarditis 12 months after therapy, all of which resolved. Other adverse events were transient, nonserious, or not treatment related. In all 8 patients with cardiac biopsy 3 months after therapy, there were higher levels of cardiac FXN (dose cohort 1, 20%; cohort 2, 81%; cohort 3, 123%). After therapy, LVMI was lower by at least 10% in 9 patients and stabilized in 8 patients. Excluding the patient with myocarditis, posttherapy values of serum hs troponin I were lower by at least 10% in 15 patients and higher by at least 10% in 2 patients.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Findings of this nonrandomized clinical trial suggest that intravenous administration of AAVrh.10hFXN was well tolerated and may be a potential treatment for FA cardiomyopathy, as evidenced by preliminary improvement in exploratory efficacy end points.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifiers:\n NCT05302271<\/jats:ext-link>\n and\n NCT05445323<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.1699","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:30:30Z","timestamp":1781710230000},"page":"709","source":"Crossref","is-referenced-by-count":6,"title":["AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia"],"prefix":"10.1001","volume":"11","author":[{"given":"Ronald G.","family":"Crystal","sequence":"first","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Weinsaft","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Kaminsky","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Caragiulo","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Savage","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, Morsani College of Medicine, University of South Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralitza H.","family":"Gavrilova","sequence":"additional","affiliation":[{"name":"Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Perlman","sequence":"additional","affiliation":[{"name":"Department of Neurology, David Geffen School of Medicine at UCLA Health Sciences, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Galbraith","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udhay","family":"Kahlon","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udhay","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kaner","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Sanders","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Vo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harini","family":"Sarva","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolan","family":"Sondhi","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishnu P.","family":"De","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason G.","family":"Mezey","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medicine, New York, New York"},{"name":"Department of Computational Biology, Cornell University, Ithaca, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Aubert","sequence":"additional","affiliation":[{"name":"Lexeo Therapeutics, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashir","family":"Khan","sequence":"additional","affiliation":[{"name":"Lexeo Therapeutics, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Selvan","sequence":"additional","affiliation":[{"name":"Lexeo Therapeutics, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narinder","family":"Bhalla","sequence":"additional","affiliation":[{"name":"Lexeo Therapeutics, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Adler","sequence":"additional","affiliation":[{"name":"Lexeo Therapeutics, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Zesiewicz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Morsani College of Medicine, University of South Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"hoi260028r1","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2022.903139","article-title":"Advantages and limitations of gene therapy and gene editing for Friedreich\u2019s ataxia.","volume":"4","author":"Sivakumar","year":"2022","journal-title":"Front Genome Ed"},{"issue":"1-2","key":"hoi260028r2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","article-title":"Mortality in Friedreich ataxia.","volume":"307","author":"Tsou","year":"2011","journal-title":"J Neurol Sci"},{"key":"hoi260028r3","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2147\/JMDH.S292945","article-title":"Friedreich ataxia: multidisciplinary clinical care.","volume":"14","author":"Lynch","year":"2021","journal-title":"J Multidiscip Healthc"},{"issue":"7","key":"hoi260028r4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(25)00175-9","article-title":"Friedreich\u2019s ataxia\u2014a rare multisystem disease.","volume":"24","author":"Reetz","year":"2025","journal-title":"Lancet Neurol"},{"issue":"1","key":"hoi260028r5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.acvd.2021.10.010","article-title":"Characterizing cardiac phenotype in Friedreich\u2019s ataxia: the CARFA study.","volume":"115","author":"Legrand","year":"2022","journal-title":"Arch Cardiovasc Dis"},{"issue":"11","key":"hoi260028r6","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2015.1855","article-title":"A 22-year follow-up study of long-term cardiac outcome and predictors of survival in Friedreich ataxia.","volume":"72","author":"Pousset","year":"2015","journal-title":"JAMA Neurol"},{"issue":"6","key":"hoi260028r7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1586\/erc.12.57","article-title":"Management and therapy for cardiomyopathy in Friedreich\u2019s ataxia.","volume":"10","author":"Lynch","year":"2012","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"hoi260028r8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/1873-3468.12928","article-title":"The role of oxidative stress in Friedreich\u2019s ataxia.","volume":"592","author":"Lupoli","year":"2018","journal-title":"FEBS Lett"},{"issue":"5","key":"hoi260028r9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/10409230600846058","article-title":"The structure and function of frataxin.","volume":"41","author":"Bencze","year":"2006","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"2","key":"hoi260028r10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/84818","article-title":"Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits.","volume":"27","author":"Puccio","year":"2001","journal-title":"Nat Genet"},{"issue":"1-3","key":"hoi260028r11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0014-5793(02)02251-2","article-title":"Frataxin knockin mouse.","volume":"512","author":"Miranda","year":"2002","journal-title":"FEBS Lett"},{"issue":"22","key":"hoi260028r12","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1093\/hmg\/ddn244","article-title":"The in vivo mitochondrial two-step maturation of human frataxin.","volume":"17","author":"Schmucker","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"13","key":"hoi260028r13","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/hmg\/ddm102","article-title":"In vivo maturation of human frataxin.","volume":"16","author":"Cond\u00f2","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"6","key":"hoi260028r14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/hmg\/9.6.887","article-title":"Recent advances in the molecular pathogenesis of Friedreich ataxia.","volume":"9","author":"Puccio","year":"2000","journal-title":"Hum Mol Genet"},{"issue":"5254","key":"hoi260028r15","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion.","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"issue":"21","key":"hoi260028r16","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1093\/hmg\/10.21.2463","article-title":"The phylogenetic distribution of frataxin indicates a role in iron-sulfur cluster protein assembly.","volume":"10","author":"Huynen","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"4","key":"hoi260028r17","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nsmb.1579","article-title":"Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscS.","volume":"16","author":"Adinolfi","year":"2009","journal-title":"Nat Struct Mol Biol"},{"issue":"33","key":"hoi260028r18","doi-asserted-by":"publisher","first-page":"29810","DOI":"10.1074\/jbc.M204675200","article-title":"Characterization of iron-sulfur protein assembly in isolated mitochondria: a requirement for ATP, NADH, and reduced iron.","volume":"277","author":"M\u00fchlenhoff","year":"2002","journal-title":"J Biol Chem"},{"issue":"43","key":"hoi260028r19","doi-asserted-by":"publisher","first-page":"9132","DOI":"10.1021\/bi1013062","article-title":"Human frataxin is an allosteric switch that activates the Fe-S cluster biosynthetic complex.","volume":"49","author":"Tsai","year":"2010","journal-title":"Biochemistry"},{"issue":"1","key":"hoi260028r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016199","article-title":"Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU\/NFS1\/ISD11 iron-sulfur assembly complex.","volume":"6","author":"Schmucker","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"hoi260028r21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0009-9120(96)00105-1","article-title":"Release kinetics of serum cardiac troponin I in ischemic myocardial injury.","volume":"29","author":"Bertinchant","year":"1996","journal-title":"Clin Biochem"},{"issue":"6","key":"hoi260028r22","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2019-0026","article-title":"The current state of biomarker research for Friedreich\u2019s ataxia: a report from the 2018 FARA biomarker meeting.","volume":"5","author":"Blair","year":"2019","journal-title":"Future Sci OA"},{"issue":"4","key":"hoi260028r23","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.ijcard.2012.04.159","article-title":"Elevation of serum cardiac troponin I in a cross-sectional cohort of asymptomatic subjects with Friedreich ataxia.","volume":"167","author":"Friedman","year":"2013","journal-title":"Int J Cardiol"},{"issue":"10","key":"hoi260028r24","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jacc.2021.01.011","article-title":"A test in context: interpretation of high-sensitivity cardiac troponin assays in different clinical settings.","volume":"77","author":"Raber","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"hoi260028r25","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S0735-1097(86)80159-0","article-title":"Cardiac involvement in Friedreich\u2019s ataxia: a clinical study of 75 patients.","volume":"7","author":"Child","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi260028r26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4330\/wjc.v11.i1.1","article-title":"Heart disease in Friedreich\u2019s ataxia.","volume":"11","author":"Hanson","year":"2019","journal-title":"World J Cardiol"},{"issue":"15-16","key":"hoi260028r27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1089\/hum.2019.363","article-title":"Stress-induced mouse model of the cardiac manifestations of Friedreich\u2019s ataxia corrected by AAV-mediated gene therapy.","volume":"31","author":"Salami","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"13-14","key":"hoi260028r28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1089\/hum.2023.020","article-title":"Identification of safe and effective intravenous dose of AAVrh.10hFXN to treat the cardiac manifestations of Friedreich\u2019s ataxia.","volume":"34","author":"Munoz-Zuluaga","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"1","key":"hoi260028r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101193","article-title":"AAV8 gene therapy reverses cardiac pathology and prevents early mortality in a mouse model of Friedreich\u2019s ataxia.","volume":"32","author":"Chang","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"hoi260028r30","doi-asserted-by":"publisher","first-page":"8391","DOI":"10.1038\/s41598-024-59060-0","article-title":"Expression and processing of mature human frataxin after gene therapy in mice.","volume":"14","author":"Rojsajjakul","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"hoi260028r31","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nm.3510","article-title":"Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia.","volume":"20","author":"Perdomini","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"hoi260028r32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/eurheartj\/eht406","article-title":"High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort.","volume":"35","author":"Zeller","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi260028r33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12968-020-00683-3","article-title":"Reference ranges (\u201cnormal values\u201d) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update.","volume":"22","author":"Kawel-Boehm","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"hoi260028r34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of omaveloxolone in Friedreich\u2019s ataxia: delayed-start analysis of the MOXIe extension.","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov Disord"},{"issue":"2","key":"hoi260028r35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.molmed.2023.12.002","article-title":"Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia.","volume":"30","author":"Pilotto","year":"2024","journal-title":"Trends Mol Med"},{"key":"hoi260028r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123053","article-title":"Characterization of clinical serum cardiac biomarker levels in individuals with Friedreich ataxia.","volume":"461","author":"Lynch","year":"2024","journal-title":"J Neurol Sci"},{"key":"hoi260028r37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijcard.2015.05.074","article-title":"The cardiomyopathy in Friedreich\u2019s ataxia\u2014new biomarker for staging cardiac involvement.","volume":"194","author":"Weidemann","year":"2015","journal-title":"Int J Cardiol"},{"issue":"2","key":"hoi260028r38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00246-024-03429-5","article-title":"Characterization of cardiac-onset initial presentation in Friedreich ataxia.","volume":"46","author":"Lynch","year":"2025","journal-title":"Pediatr Cardiol"},{"issue":"8","key":"hoi260028r39","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1097\/HJH.0b013e328302ca14","article-title":"Effects of papillary muscles and trabeculae on left ventricular quantification: increased impact of methodological variability in patients with left ventricular hypertrophy.","volume":"26","author":"Janik","year":"2008","journal-title":"J Hypertens"},{"issue":"1","key":"hoi260028r40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1161\/CIRCIMAGING.111.966754","article-title":"Improved left ventricular mass quantification with partial voxel interpolation: in vivo and necropsy validation of a novel cardiac MRI segmentation algorithm.","volume":"5","author":"Codella","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"hoi260028r41","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1097\/HJH.0b013e328362d935","article-title":"Geometry-independent inclusion of basal myocardium yields improved cardiac magnetic resonance agreement with echocardiography and necropsy quantified left-ventricular mass.","volume":"31","author":"Simprini","year":"2013","journal-title":"J Hypertens"},{"issue":"6","key":"hoi260028r42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1212\/NXG.0000000000000371","article-title":"Psychometric properties of the Friedreich ataxia rating scale.","volume":"5","author":"Rummey","year":"2019","journal-title":"Neurol Genet"},{"issue":"7","key":"hoi260028r43","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","article-title":"Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale.","volume":"64","author":"Subramony","year":"2005","journal-title":"Neurology"},{"issue":"23-24","key":"hoi260028r46","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1089\/hum.2020.116","article-title":"Quantitative whole-body imaging of I-124-labeled adeno-associated viral vector biodistribution in nonhuman primates.","volume":"31","author":"Ballon","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"9","key":"hoi260028r47","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/acn3.332","article-title":"Progression of Friedreich ataxia: quantitative characterization over 5 years.","volume":"3","author":"Patel","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"hoi260028r48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209410","article-title":"Differences in the determinants of right ventricular and regional left ventricular long-axis dysfunction in Friedreich ataxia.","volume":"13","author":"Peverill","year":"2018","journal-title":"PLoS One"},{"issue":"13","key":"hoi260028r49","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.111.059477","article-title":"The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms.","volume":"125","author":"Weidemann","year":"2012","journal-title":"Circulation"},{"issue":"15-16","key":"hoi260028r50","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1089\/hum.2020.053","article-title":"Defining transcription regulatory elements in the human frataxin gene: implications for gene therapy.","volume":"31","author":"Li","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"9","key":"hoi260028r51","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1177\/0883073812448461","article-title":"Cross-sectional analysis of electrocardiograms in a large heterogeneous cohort of Friedreich ataxia subjects.","volume":"27","author":"Schadt","year":"2012","journal-title":"J Child Neurol"},{"issue":"1","key":"hoi260028r52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1086\/513887","article-title":"Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat.","volume":"61","author":"Monr\u00f3s","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"5","key":"hoi260028r53","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehq443","article-title":"Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome.","volume":"32","author":"Raman","year":"2011","journal-title":"Eur Heart J"},{"issue":"9","key":"hoi260028r54","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0883073812448535","article-title":"Cardiomyopathy in Friedreich ataxia: clinical findings and research.","volume":"27","author":"Payne","year":"2012","journal-title":"J Child Neurol"},{"key":"hoi260028r44","volume-title":"Sponsor Responsibilities\u2014Safety Reporting Requirements and Safety Assessment for IND and Bioavailability\/Bioequivalence Studies: Guidance for Industry","author":"US Food and Drug Administration","year":"2025"},{"key":"hoi260028r45","volume-title":"Investigator Responsibilities\u2014Safety Reporting for Investigational Drugs and Devices: Guidance for Investigators, Industry, and Institutional Review Boards","author":"US Food and Drug Administration","year":"2025"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2850507\/jamacardiology_crystal_2026_oi_260028_1786123777.22491.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:00:48Z","timestamp":1786546848000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2850507"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.1699","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}